Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases

Next Previous
Trial Profile

A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Radium 223 chloride (Primary)
  • Indications Adenocarcinoma; Bone metastases; Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ALSYMPCA
  • Sponsors Algeta; Bayer

Most Recent Events

  • 23 Feb 2026 Actual primary completion date changed from 1 Jul 2011 to 15 Jul 2011.
  • 25 May 2023 According to a Bayer media release, data from this study will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6, 2023.
  • 21 Sep 2020 Results of post-hoc analysis investigating the role of NLR, neutrophilia and lymphopenia on the outcome of mCRPC patients treated with Ra-223 presented at the 45th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top